Celgene Corp (CELG) 86.05 $CELG
Midday Glance: Biotechnology companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Celgene Up 17.1% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Thu Jul 10, 9:55AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 2 months, Celgene has returned 17.08% as of today's recent price of $86.56.
Celgene Gets Bad News, Shares Climb Anyway
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 7:46AM CDT
Otezla, one of the big potential blockbuster drugs Celgene is depending on to expand its revenue generation beyond Revlimid, failed a phase 3 trial in ankylosing spondylitis. And yet, at the end of the first full market day after announcing the...
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
'Fast Money' Recap: Digging Into Oil Prices
at The Street - Thu Jul 10, 4:00AM CDT
The trading panel looked at whether WTI will go lower, how that will affect transportation stocks and how successful a Kim Kardashian mobile game app can be.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Midday Glance: Biotechnology companies
AP - Wed Jul 16, 1:54PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Jul 16, 10:11AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Are These the Best Big Biotech Stocks for Your Portfolio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 4:00PM CDT
Gilead Sciences has had a banner year. Sovaldi, the hepatitis c cure, was a huge seller in its first full quarter on the market, netting $2.3 billion and blowing away analyst expectations. Celgene has had a more mixed experience this year,...
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 10:30AM CDT
Celgene's (CELG) Otezla failed to meet the primary endpoint in a late stage study.
Celgene Up 17.1% Since SmarTrend Uptrend Call (CELG)
Comtex SmarTrend(R) - Thu Jul 10, 9:55AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 2 months, Celgene has returned 17.08% as of today's recent price of $86.56.
Celgene Gets Bad News, Shares Climb Anyway
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 10, 7:46AM CDT
Otezla, one of the big potential blockbuster drugs Celgene is depending on to expand its revenue generation beyond Revlimid, failed a phase 3 trial in ankylosing spondylitis. And yet, at the end of the first full market day after announcing the...
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM
at The Street - Thu Jul 10, 5:00AM CDT
Cramer says Williams is a bargain, Unum is a slow and steady grower and Alcoa is reinventing itself.
'Fast Money' Recap: Digging Into Oil Prices
at The Street - Thu Jul 10, 4:00AM CDT
The trading panel looked at whether WTI will go lower, how that will affect transportation stocks and how successful a Kim Kardashian mobile game app can be.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
